“Ozempic eyes” is an informal term for a rare but serious eye condition linked to semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus. The medical name is non-arteritic anterior ischemic optic neuropathy, or NAION, a condition where blood flow to the optic nerve is disrupted, causing sudden vision loss. In early 2025, the European Medicines Agency officially classified NAION as a “very rare” side effect of semaglutide, meaning it may affect up to 1 in 10,000 people taking the drug.
What NAION Actually Is
NAION is the most common cause of sudden optic nerve damage in adults over 50. It happens when the small blood vessels supplying the front portion of the optic nerve fail to deliver enough blood, essentially starving the nerve tissue. The result is rapid, painless vision loss, usually in one eye. It’s not an infection, not inflammation, and not related to the cosmetic changes in facial appearance that some people on weight-loss drugs experience (sometimes called “Ozempic face”). This is a neurological event affecting the eye’s connection to the brain.
NAION occurs in the general population at a rate of roughly 2 to 10 cases per 100,000 people per year, with higher rates among older adults and people with diabetes. What drew attention to semaglutide specifically was research suggesting the drug may roughly double that already-low baseline risk.
How Semaglutide Changes the Risk
The strongest signal came from a study at a single academic medical center, published in JAMA Ophthalmology, that found striking numbers. Among patients with type 2 diabetes, those taking semaglutide had a cumulative NAION incidence of 8.9% over three years, compared to 1.8% in patients on other diabetes medications. For people using semaglutide for weight loss (without diabetes), the gap was even wider: 6.7% versus 0.8%. Those translate to hazard ratios of 4.28 for diabetic patients and 7.64 for weight-loss patients, meaning the semaglutide group developed NAION at several times the rate of comparison groups.
However, a larger follow-up analysis using broader insurance databases found a more modest signal. When researchers compared semaglutide users to people taking other common diabetes drugs like sitagliptin or glipizide, the differences in NAION risk were not statistically significant. A self-controlled analysis, which compares each patient’s own risk during periods on and off the drug, did find a statistically significant 32% to 50% increase in NAION incidence during semaglutide exposure. The risk was also no different between semaglutide and dulaglutide, another drug in the same class.
So the picture is nuanced. There does appear to be a real, modest increase in risk, but the absolute numbers remain very small. The EMA’s conclusion puts it at roughly one additional case of NAION per 10,000 person-years of treatment.
Symptoms to Recognize
NAION typically strikes suddenly, often noticed first thing in the morning upon waking. The hallmark is painless vision loss in one eye. You might notice a dark area in your upper or lower visual field, as if a curtain has been pulled partway across your sight. The severity varies widely. Some people retain near-normal sharpness while losing a chunk of peripheral vision, while others experience profound loss, with acuity dropping to the 20/60 to 20/200 range or worse.
About 10% to 15% of people with NAION do experience some aching in or around the affected eye, but pain with eye movement is not typical. The vision loss usually stabilizes within two to three days, meaning the damage happens fast and then plateaus rather than gradually worsening over weeks.
If you notice any sudden change in vision while taking semaglutide, that warrants urgent evaluation by an eye specialist, not a wait-and-see approach. Early assessment can rule out other treatable causes of vision loss that mimic NAION.
Recovery and Long-Term Outlook
The prognosis for NAION is sobering. There is currently no proven treatment. A major clinical trial of an investigational drug called QPI-1007 failed to show benefit in preventing further vision loss after an acute episode. The condition causes irreversible damage to the optic nerve in most cases.
Data from the Ischemic Optic Neuropathy Decompression Trial provides the best picture of natural recovery. About 30% of patients regain meaningful vision (three or more lines on a standard eye chart) within two years. Another 20% actually lose additional vision over that period. For the remaining roughly half, vision stays at whatever level it reached in those first few days. The sudden, often permanent nature of the loss carries a real psychological burden, particularly because there’s little that can be done to reverse it.
Who Faces the Highest Risk
Certain factors raise baseline NAION risk regardless of medication use. People with diabetes already face elevated rates, as do those with high blood pressure, sleep apnea, and a specific anatomical trait called a “disc at risk,” where the optic nerve head is small and crowded. If you have several of these risk factors and are considering semaglutide, that context matters for weighing the overall benefit of the drug against this rare but serious possibility.
The data suggesting a higher relative risk in the weight-loss population (people without diabetes) is particularly noteworthy. That group had a lower baseline rate of NAION to begin with, so the proportional jump was larger. Whether this reflects a true biological difference or a quirk of the study’s small sample size (361 semaglutide users in the overweight group) remains an open question.
What This Means if You Take Semaglutide
The overall risk remains very low in absolute terms. For most people, the cardiovascular and metabolic benefits of semaglutide will far outweigh the chance of developing NAION. But “very rare” is not “nonexistent,” and this side effect is unusually consequential because the vision loss is typically permanent and untreatable.
Getting a baseline eye exam before starting semaglutide is a reasonable precaution, particularly if you have diabetes, since screening for diabetic retinopathy is already recommended before initiating the drug. Knowing the status of your optic nerves and retinal health gives both you and your doctor a reference point. If you ever wake up with sudden, painless vision loss in one eye while taking the medication, seek same-day evaluation from an ophthalmologist rather than waiting for a routine appointment.